Methotrexate Injection, Solution
Product Images NDC 55150-510

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Methotrexate (NDC 55150-510). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eugia Us Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Package Label-principal Display Panel (50 mg per 2 mL)

Label for Methotrexate Injection, USP 50 mg per 2 mL (25 mg/mL) preservative-free solution. The sterile isotonic injection is for intravenous, intramuscular, subcutaneous, and intrathecal use only, packaged in a 2 mL single-dose vial. Manufactured in India for Eugia US LLC, with storage instructions from 20°C to 25°C and warnings to protect from light.*

FDA Label Image

Package Label-principal Display Panel (250 mg per 10 mL)

Label for Methotrexate Injection, USP 250 mg per 10 mL (25 mg/mL) solution. It is preservative free and marked as a hazardous drug. Intended for intravenous, intramuscular, subcutaneous, and intrathecal use only. The label states it is a sterile isotonic solution in a 10 mL single-dose vial. Manufactured for Eugia US LLC, with storage instructions and ingredient details included.*

FDA Label Image

Package Label-principal Display Panel (250 mg per 10 mL- Container-Carton (1's Pack))

Methotrexate Injection, USP 250 mg per 10 mL (25 mg/mL) solution label for a single-dose vial. The label states it is preservative free, a hazardous drug, and intended for intravenous, intramuscular, subcutaneous, and intrathecal use. Distributed by Eugia US LLC. The vial contains sterile isotonic solution with storage instructions and ingredient details.*

FDA Label Image

Package Label-principal Display Panel (50 mg per 2 mL)

Packaging label for Methotrexate Injection, USP 50 mg per 2 mL (25 mg/mL) sterile isotonic solution. It is preservative-free and indicated for intravenous, intramuscular, subcutaneous, and intrathecal administration. The package contains one 2 mL single-dose vial. Distributed by Eugia US LLC, the label includes storage instructions and a barcode on the side panel.*

FDA Label Image

Package Label-principal Display Panel (50 mg per 2 mL)

Methotrexate Injection, USP 50 mg per 2 mL (25 mg/mL) preservative free, hazardous drug, for intravenous, intramuscular, subcutaneous, and intrathecal use. Sterile isotonic solution in a package of 5 single-dose 2 mL vials. Labeler: Eugia US LLC. The packaging includes storage instructions and a bar code.*

FDA Label Image

Package Label-principal Display Panel (100 mg per 4 mL)

Label for Methotrexate Injection, USP 100 mg per 4 mL (25 mg/mL) solution in a 4 mL single-dose vial. It is preservative-free and intended for intravenous, intramuscular, subcutaneous, and intrathecal use. The product is a sterile isotonic solution labeled as a hazardous drug and is manufactured for Eugia US LLC, E. Windsor, NJ.*

FDA Label Image

Package Label-principal Display Panel (100 mg per 4 mL)

Methotrexate Injection, USP 100 mg per 4 mL (25 mg/mL) vial label, preservative-free hazardous drug for intravenous, intramuscular, subcutaneous, and intrathecal use. Single-dose sterile isotonic solution vial distributed by Eugia US LLC. Storage instructions and ingredient information included.*

FDA Label Image

Package Label-principal Display Panel (100 mg per 4 mL)

Packaging label for Methotrexate Injection, USP 100 mg per 4 mL (25 mg/mL) preservative-free solution. The label indicates it is for intravenous, intramuscular, subcutaneous, and intrathecal use. It contains 10 single-dose vials of 4 mL each. Distributed by Eugia US LLC, made in India, and includes storage instructions and inactive ingredients information.*

FDA Label Image

Package Label-principal Display Panel (200 mg per 8 mL)

Label for Methotrexate Injection, USP 200 mg per 8 mL (25 mg/mL) solution vial. The label states it is preservative free and hazardous, for intravenous, intramuscular, subcutaneous, and intrathecal use. It is an 8 mL single-dose sterile isotonic solution vial. Manufactured in India for Eugia US LLC.*

FDA Label Image

Package Label-principal Display Panel (200 mg per 8 mL)

Packaging label for Methotrexate Injection USP, 200 mg per 8 mL (25 mg/mL), preservative free, labeled as a hazardous drug. The label states the product is for intravenous, intramuscular, subcutaneous, and intrathecal use only. It is a sterile isotonic solution supplied in a single-dose 8 mL vial. Distributed by Eugia US LLC, the label includes storage instructions and inactive ingredient information.*

FDA Label Image

Package Label-principal Display Panel (200 mg per 8 mL)

Box packaging label for Methotrexate Injection, USP 200 mg per 8 mL (25 mg/mL) solution. The label states it is preservative free and a hazardous drug for intravenous, intramuscular, subcutaneous, and intrathecal use. Pack contains 10 single-dose vials of 8 mL each. Distributed by Eugia US LLC, made in India.*

FDA Label Image

Checmical Structure (Methotrexate Str)

Chemical structure diagram of methotrexate, showing its molecular framework with multiple nitrogen-containing rings, an amine group, carboxyl groups, and aromatic components, consistent with the active ingredient methotrexate.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.